Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
As official campaigning got underway for the December 14 Lower House race in Japan, the pharmaceutical industry is already looking towards the post-election tax debate that is expected to culminate in the last two weeks of this year. The paramount…
To read the full story
Related Article
- Japan Tax Reform Plan Will Be Compiled by Year-End: Abe
December 16, 2014
- JPMA Tones Down Demand on R&D Tax Credit System, Calls for “Maintenance” Instead of “Perpetuation”
October 20, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
REGULATORY
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
- 679 Safety Reports Logged for Regenerative Medical Products in 2H FY2025
August 21, 2026
- Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
- DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…